Table 3.
Studies 1–3 | ||
---|---|---|
Psychosis Group | F = 1.82 | d = 0.26 |
Sex | F = 0.24 | d = 0.06 |
Strategy | F = 79.04*** | d = 0.91 |
Psychosis Group × Sex | F = 2.14 | d = 0.31 |
Psychosis Group × Strategy | F = 977*** | d = 0.68 |
Sex × Strategy | F = 1.28 | d = 0.17 |
Psychosis Group × Sex × Strategy | F = 6.42** | d = 0.59 |
One-Way ANOVAs Across Groups | ||
Reappraisal - Female | F = 759*** | d = 0.61 |
Suppression - Female | F = 1.82 | d = 0.30 |
Reappraisal - Male | F = 1.81 | d = 0.29 |
Suppression - Male | F = 3.55* | d = 0.40 |
One-Way ANOVAs Within Groups Comparing Sexes | ||
Reappraisal | ||
PLE (M vs F) | F = 7.68** | d = 0.35 |
CHR (M vs F) | F = 0.67 | d = 0.32 |
SZ (M vs F) | F = 0.31 | d = 0.14 |
Suppression | ||
PLE (M vs F) | F = 11.02*** | d = 0.42 |
CHR (M vs F) | F = 4.29* | d = 0.81 |
SZ (M vs F) | F = 3.11 | d = 0.51 |
Note.
p < 0.001;
p < 0.01;
p < 0.05.
PLE = individuals with psychotic-like experiences; NPLE = individuals without psychotic-like experiences; CHR = individuals at clinical high-risk; CN = controls; SZ = schizophrenia outpatients; M = males; F = females.